Identification of triazolopyridazinones as potent p38alpha inhibitors.
Herberich, B., Jackson, C., Wurz, R.P., Pettus, L.H., Sherman, L., Liu, Q., Henkle, B., Saris, C.J., Wong, L.M., Chmait, S., Lee, M.R., Mohr, C., Hsieh, F., Tasker, A.S.(2012) Bioorg Med Chem Lett 22: 1226-1229
- PubMed: 22196117 
- DOI: 10.1016/j.bmcl.2011.11.067
- Primary Citation of Related Structures:  
3U8W - PubMed Abstract: 
Structure-activity relationship (SAR) investigations of a novel class of triazolopyridazinone p38α mitogen activated protein kinase (MAPK) inhibitors are disclosed. From these studies, increased in vitro potency was observed for 2,6-disubstituted phenyl moieties and N-ethyl triazolopyridazinone cores due to key contacts with Leu108, Ala157 and Val38 ...